CrossrefInfokarte
PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan
Journal of Gynecologic Oncology · 2026 · 37 (4)
DOI: 10.3802/jgo.2026.37.e75 ↗Abstract
Kein Abstract verfügbar.
EUVIMED